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Dermatoses are skin diseases caused by lowered level of lipids in the intercellular lipid matrix of skin’s uppermost layer 
stratum corneum. A promising therapy is the application of liposomally formulated skin lipids (ceramides, cholesterol, 
fatty acids). These so called cerosomes proved very effective in disrupted skin barrier repair; however, they aim primarily 
on a mechanical surface restoration. For this reason an interesting idea is to combine the cerosomes and anti-inflammatory 
drugs (such as hydrocortisone) used for the treatment of pathophysiological processes in the skin. Unfortunately, 
liposomes generally show low drug encapsulation rates, hence they would not be very effective carriers. On the other 
hand, great encapsulation effectivity can be found in lipid nanocapsules (LNCs). We therefore aimed to create a combined 
system cerosomes-LNCs that would ensure the skin barrier restoration thanks to the ceramides and simultaneously 
effectively deliver hydrocortisone as a representative of anti-inflammatory drugs into lower layers of the skin. In this 
work, we characterized the formulations by dynamic light scattering and transmission electron microscopy to assess their 
size and morphology.  
 
Keywords: atopic dermatitis, ceramides, cerosomes, lipid nanocapsules, hydrocortisone 
 
INTRODUCTION 
Human skin is the most effective barrier protecting our 
bodies from xenobiotics, UV light or bacteria. It ensures 
the proper thermoregulation and limits the water loss. 
All these vital properties are possible thanks mainly to 
the uppermost layer of the skin – stratum corneum (SC) 
and its unique composition. Its main building blocks are 
the skin cells keratinocytes that are connected by a 
complex intercellular lipid matrix. This lipid matrix 
consists of ceramides (40–50%), fatty acids (15–25%), 
cholesterol (20–25%) and cholesterol sulfate (5–10 %) 
(Harding, 2004). 
Skin, as any other organ, can be affected by a disease 
that changes or limits its basic functions. The most 
common ones one can encounter nowadays are atopic 
dermatitis, or generally dermatoses, or psoriasis. These 
diseases are accompanied by loss of skin hydration, 
dryness and elevated permeation rates of xenobiotics. 
The affected sites are reddish and itchy, which can lead 
to the necessity to scratch the area and therefore to the 
probability to carry an infection into the deeper layers of 
the skin and to further spread of the disease. One of the 
common signs of the diseases compromising the skin 
barrier is the change in the SC lipid matrix composition. 
The most notable change here is a depletion of 
ceramides and long chain fatty acids (Shao et al., 2016; 
Wolf & Wolf, 2012).  
The typical treatment of skin diseases is the application 
of ointments and creams, whose task is to ensure 
sufficient skin hydration and provide a healing 
environment. The most widely used therapy is 
application of corticosteroids and calcineurin inhibitors. 
These drugs are however administered in a form of 
suspension or dispersion, which are forms that cannot 
ensure the best biological availability of topically 
applied drugs. For this reason, we focus on the 
development of an alternative therapy concerning the 
direct application of the skin lipids, namely ceramides 
that help to restore the disrupted skin barrier properties.  
Currently, we have a very effective liposomal system 
containing skin lipids with a composition imitating the 
SC lipid matrix – so called cerosomes. These cerosomes 
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are able to effectively restore chemically disrupted skin 
barrier (Vovesná, Zhigunov, Balouch, & Zbytovská, 
2021). However, their effect is directed only to the outer 
surface disease manifestations. It is therefore vital to 
enhance this system and target even the 
pathophysiological processes in the deeper skin layers. 
For this purpose, we already have an experience with 
hydrocortisone-loaded cerosomes. Nevertheless, the 
encapsulation efficiency of cerosomes was not ideal and 
the system would not be as effective as needed. 
Typically for a topical administration of drugs, we use 
another carriers – lipid nanocapsules (LNCs). These 
nanoparticles are stable for a long time with great 
capability to encapsulate wide variety of drugs, 
including HC. We also know, that LNCs help to 
concentrate HC into SC and epidermis; however, they 
do not restore the skin barrier.  
For this reason we aim to create a combined system of 
cerosomes and LNCs with encapsulated anti-
inflammatory drug (eg. hydrocortisone). We will 
characterize the morphology of prepared particles and 
ultimately test their efficacy in disrupted skin repair and 
HC administration.  
 
RESEARCH CONCEPT 
Preparation of cerosomes-LNC system 
The cerosomes are prepared by modified method of thin 
lipid film hydration. At first, all the lipids, ceramides 3 
and 6, cholesterol and stearic acid are weighed in a 
round bottom flask and dissolved in a chloroform : 
methanol mixture. Hydrocortisone (HC) or HC-butyrate 
(HC-B) is added to this mixture as well. The ratio of 
these lipids and the drug is equimolar to best simulate 
the environment in the lipid matrix and to introduce 
sufficient amount of the drug into the formulation 
(Table 1). The solvents are then evaporated on a rotary 
evaporator until a thin film is formed on the walls of the 
flask. This film is further hydrated by phosphate 
buffered saline (PBS) solution with 10 % urea addition 
(PBS+U). The flask is alternatively placed in a heater on 
95 °C and shook on a vortex until all the lipids from the 
flask walls are dissolved. Next, LNCs are prepared by 
the phase inversion temperature method (Heurtault, 
Saulnier, Pech, Proust, & Benoit, 2002). An MCT oil 
(Miglyol 812 N), nonionic (Kolliphor HS 15) and 
amphoteric (Phospholipon 90G) surfactants are weighed 
in a beaker. HC or HC-B are also added to this mixture. 
PBS with 10 % addition of urea (PBS+U) is added and 
the whole is placed on a heater (Table 1). The mixture is 
heated three times in the range from 50 to 85 °C. After 
the third heating cycle, the mixture is diluted with ice 
cold PBS+U. The cold shock induces the nanoparticle 
formation and also the encapsulation of the drug.   
Table 1: Composition of prepared nanoparticular 
systems.  
Cerosomes LNCs 
Compound wt% wt% Compound wt% 
Ceramide 3 0.18 0.17 Miglyol 30.0 
Ceramide 6 0.18 0.18 Kolliphor 20.0 
Cholesterol 0.22 0.26 Phospholipon 1.5 
Stearic acid 0.24 0.23 HC, HC-B 0.75 
HC 0.18  PBS+U 15.0 




Urea 10.0 10.0   
PBS 89.0 89.0   
 
To combine these two systems, we took two approaches. 
One is to add the LNCs to the cerosomes. A freshly 
prepared batch of LNCs was added onto the thin lipid 
cerosomal film. The film was then hydrated and 
vortexed the same way as described above. The second 
variation of the preparation is to add the cerosomes to 
the LNCs. At first, cerosomes were prepared as 
described and then they were added to the LNC 
preparation instead the sole PBS+U.  
Particle characterization 
We characterized our nanoparticulate systems by 
dynamic light scattering (DLS) in order to get the 
information about the size of present particles. We 
describe our systems by number mean values of the size 
when we show characteristics of sole cerosomes or 
LNCs. Then to describe the combined system, we use 
volume mean values of the size for the reason that it is 
crucial to see both types of the particles largely differing 
in their sizes.  
We also established the encapsulation efficiency (EE) of 
cerosomes, LNCs and cerosomes-LNCs for 
hydrocortisone and hydrocortisone-butyrate. The EE 
was determined by ultrafiltration of a sample through 
Centrisart 20 kDa MWCO filtration units and 





RESULTS AND DISCUSSION 
At first, we prepared and characterized both systems 
(cerosomes and LNCs) respectively to find the maximal 
content of the drug (HC, HC-B) and other limits for both 
formulations. Loading cerosomes with a drug like HC or 
HC-B did not pose any challenge in terms of preparation 
conditions. It was possible to hydrate the lipid films 
containing both drugs in normal hydrating time and 
temperature (6 h, 95 °C). The resulting liposomal 
formulation was of a smooth white appearance without 
any visible large particles, crystals or aggregates. The 
particles were stored in a dark place at laboratory 
temperature in order to minimize influences on the 
particle degradation. Liposomes prepared by film 
hydration method are large multilamellar vehicles with 
quite notable variations in size leading to higher values 
of polydispersity index (PDI). Our prepared cerosomes 
showed following characteristics: HC-cerosomes were 
of 651 ± 25 nm in size with PDI = 0.37 ± 0.12. HC-B-
cerosomes did not differ significantly; they contained 
particles with size of 773 ± 45 nm, PDI = 0.45 ± 0.10. 
As the particle size is concerned, drug-loaded cerosomes 
were in every case smaller than cerosomes prepared 
without an API (active pharmaceutical ingredient). To 
show the difference, we can compare CER3+CER6 type 
of cerosomes prepared in our previous work (Vovesná 
et al., 2021). There we show the cerosomes to be 1196 ± 
238 nm large with PDI of 0.15 ± 0.02. That is notably 
bigger size than HC or HC-B loaded cerosomes with the 
same composition. We assume that this fact can be 
ascribed to the molecular shape of both corticoids. The 
base structure of the sterol core of HC and HC-B is 
similar to the structure of cholesterol; therefore, HC 
could have the tendency to incorporate itself into the 
bilayered mixed structure of the cerosomes, opposed to 
more common adherence or bonding onto or into the 
liposomes. For this reason, we also chose the total 
content of HC and HC-B to be equimolar with all other 
components. Ultimately, the lipids form 1 % of the total 
formulation and HC or HC-B stand for approximately 
0.18 % of total. The cerosomes as other liposomes do 
not possess great encapsulating capacity. That is also the 
main reason for this work on a combined system. In our 
case the encapsulation efficiency (EE) for HC was 25.3 
± 1.4 % and drug load (DL) 0.3 %. For HC-B these 
values were similar: EEHCB,cersosomes = 20.6 ± 0.9 and 
DLHCB,cerosomes = 0.2 ± 0.1 %. The encapsulation values 
around 20 % are in the expected range. DL usually 
reaches values < 10 % and for liposomes, these values 
are as always low.  
The second formulation that forms the combination are 
the LNCs. The composition of the LNCs in this work 
was optimized to hold the highest amount of HC or HC-
B possible without influencing the particle stability. The 
maximal content of the corticoids in LNCs is 0.75 % of 
the total formulation for both APIs. The size of empty 
LNC particles prepared with this composition (Table 1) 
is 101 ± 3 nm with PDI = 0.06. This size is comparable 
to other LNCs with quite same composition prepared in 
our laboratory (Pytlíková, 2020) that were sized circa 
115 nm with PDI of 0.07. The introduction of an API 
into this system changed its characteristics only 
minimally. HC-LNC contained particles of 105 ± 2 nm, 
PDI = 0.08 and HC-B-LNC were sized 113 ± 1 nm, PDI 
= 0.09. These changes are very slight and can even be 
ascribed to variation in preparation and measurements. 
As was proposed, LNCs have great encapsulation ability 
for vast variety of drugs. Our system is not an exception, 
even though the selected corticoids are generally quite 
inert and insoluble. The EE for hydrocortisone was as 
high as 87.6 ± 3.1 % and DL was 1.0 ± 0.1 %. HC-B-
LNCs encapsulated the drug by 85.8 ± 1.7 % with DL of 
1.0 ± 0.1 % also. Additionally, all these characteristics 
did not change significantly during 2 weeks storage 
time, implying that HC and HC-B loaded LNCs are 
stable system capable to incorporate notable amount of 
the APIs.  
For the last part of this work, we combined the two 
described systems in order to create a complex renewing 
and healing treatment for dermatitic conditions. The first 
approach was to use the HC(B)-LNCs as the aqueous 
phase for the HC(B)-cerosomes. However, the heating 
cycles at 95 °C seemed to disrupt and break the 
constitution of the LNCs due to such high applied heat. 
The DLS measurement revealed only particles sized 
around 1 µm, which suggests the presence of liposomal 
structures, but not the smaller LNC ones. It was not 
possible to lower the hydrating temperature for the 
ceramides would not hydrate in the needed time. We 
therefore applied another method for this combination. 
LNCs were again added onto the lipid film and the 
whole flask was placed in a water bath set at 40 °C and 
the mixture was intensely mixed overnight to simulate a 
kind of high shear homogenization conditions. After this 
time, the lipid film was completely hydrated from the 
flask walls; however, there could still be seen larger 
crystals of incompletely dissolved components of the 
formulation. The second approach to the preparation 
was to use the HC(B)-cerosomes as the aqueous phase 
of the HC(B)-LNCs. Their preparation process was not 
hindered by the exchange of PBS+U for the cerosomes 
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and was completed as described in the methods section. 
The resulting formulation was homogeneous, opalesque 
without visible particles. The DLS measurement 
confirmed the presence of two sizes of particles if 
evaluated by volume mean. For HC variation the first 
and larger peak was at 98 ± 2 nm at should belong to the 
LNC part of the combination. The second peak was 
visibly smaller and positioned at 835 ± 11 nm, which 
accords with the size of cerosomes. For HC-B the result 
was really similar. It was possible to obtain a 
formulation with two distinct sizes of 116 ± 5 nm and 
956 ± 45 nm belonging to LNCs and cerosomes 
respectively. The EE and DL for this system are yet to 
be determined. Nevertheless, from the fact that the 
formulations did not contain any visible undissolved 
crystals, which it otherwise would if the HC and HC-B 
were not dissolved, we can expect the encapsulation 
rates to be at least as good as for the LNCs, but with the 




In this work we focused on a preparation of 
nanoparticulate systems for topical delivery of 
hydrocortisone and hydrocortisone-butyrate. It was 
possible to prepare lipid nanocapsules containing 
0.75 % of HC or HC-B with 85 % encapsulation 
efficiency. Next, we successfully prepared cerosomes 
mimicking the composition of stratum corneum lipid 
matrix loaded with 0.18 % of HC and HC-B. In order to 
enhance the efficiency of dermatitic conditions 
treatment, we successfully combined the two systems 
and characterized it for the presence of both 
formulations. We propose that such complex 
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API Active pharmaceutical ingredient 
DLS Dynamic light scattering 
EE Encapsulation efficiency 
HC Hydrocortisone 
LNC Lipid nanocapsule 
PBS Phosphate buffered saline 
SC Stratum corneum 
TEM Transmission electron microscopy 
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